Clinical Trial

Study of LM-299 in Subjects Advanced Malignant Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours.. For Phase II Dose Expansion Stage, to assess the antitumor activity of LM-299 in patients with various advanced solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-10-17; most recent amendment 2025-04-29.
Trial Details
NCT Number NCT06650566
Lead Sponsor LaNova Medicines Limited
Conditions Malignant Tumors
Enrollment 108 participants
Start Date 2024-10-09
Primary Completion 2026-12 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-05-02